Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement

Nanotechnology

Volumn 21, Issue 2, 2010, Pages

  Shen, Jie ^a   Sun, Minjie ^a   Ping, Qineng ^a   Ying, Zhi ^a   Liu, Wen ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LINES; DRUG LOADING CAPACITY; EMULSION TECHNOLOGY; EX-VIVO; FLUORESCENCE IMAGING; HUMAN CORNEAL; IN-VITRO; IN-VIVO; LIPID NANOPARTICLES; NANOCARRIERS; NANOSTRUCTURED LIPID CARRIERS; OCULAR DRUG DELIVERY; OCULAR TISSUE; PHYSICOCHEMICAL PROPERTY; SURFACE EXPOSURE; SUSTAINED DRUG RELEASE;

CELL CULTURE; DRUG DELIVERY; EMULSIFICATION; FLUORESCENCE; NANOPARTICLES;

LIQUIDS;

FLUORESCEIN; LIPID; MIGLYOL; NANOCARRIER; NANOPARTICLE; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA; CORNEA EPITHELIUM; CYTOTOXICITY; DRUG DELIVERY SYSTEM; EMULSION; EX VIVO STUDY; EYE DISEASE; FLUORESCENCE; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LIQUID; MELTING POINT; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RABBIT; SUSTAINED DRUG RELEASE; ANIMAL; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; MATERIALS TESTING; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NANOMEDICINE; SOLUTION AND SOLUBILITY; SYNTHESIS;

ANIMALS; CELL LINE; DRUG CARRIERS; EPITHELIUM, CORNEAL; HUMANS; LIPIDS; MATERIALS TESTING; METABOLIC CLEARANCE RATE; NANOMEDICINE; NANOPARTICLES; RABBITS; SOLUTIONS;

EID: 71549165819     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/21/2/025101     Document Type: Article

References (31)

1. Davies N M 2000 Biopharmaceutical considerations in topical ocular drug delivery Clin. Exp. Pharmacol. Physiol. 27 558-62
2. De Campos A M, Snchez A and Alonso M J 2001 Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A Int. J. Pharm. 224 159-68
3. Durrani A M, Davies N M, Thomas M and Kellaway I W 1992 Pilocarpine bioavailability from a mucoadhesive liposomal ophthalmic drug delivery system Int. J. Pharm. 88 409-15
4. Kaur I P, Garg A, Singla A K and Aggarwal D 2004 Vesicular systems in ocular drug delivery: an overview Int. J. Pharm. 269 1-14
5. Vandervoort J and Ludwig A 2004 Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use Eur. J. Pharm. Biopharm. 57 251-61
6. Yang S C, Lu L F, Cai Y, Zhu J B, Liang B W and Yang CZ 1999 Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain J. Control. Release 59 299-307
7. Müller R H, Radtke M and Wissing S A 2002 Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations Adv. Drug Deliv. Rev. 54 131-55
8. Cavalli R, Gasco M R, Chetoni P, Burgalassi S and Saettone MF 2002 Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin Int. J. Pharm. 238 241-5 (Pubitemid 34457892)
9. Li X, Nie S F, Kong J, Li N, Ju C Y and Pan W S 2008 A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers Int. J. Pharm. 363 177-82
10. Shen J, Wang Y, Ping Q, Xiao Y and Huang X 2009 Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery J. Control. Release 137 217-23
11. Freitas C and Müller R H 1999 Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase Eur. J. Pharm. Biopharm. 47 125-32 (Pubitemid 29185115)
12. Müller R H, Radtke M and Wissing S A 2002 Nanostructured lipid matrices for improved microencapsulation of drugs Int. J. Pharm. 242 121-8
13. Souto E B, Wissing S A, Barbosa C M and Müller R H 2004 Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations Eur. J. Pharm. Biopharm. 58 83-90
14. Jenning V, Thünemann A F and Gohla S H 2000 Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids Int. J. Pharm. 199 167-77 (Pubitemid 30236188)
15. Hu F Q, Jiang S P, Du Y Z, Yuan H, Ye Y Q and Zeng S 2005 Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system Colloids Surf. B 45 167-73
16. Teeranachaideekul V, Boonme P, Souto E B, Müller R H and Junyaprasert V B 2008 Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC J. Control. Release 128 134-41
17. Gupta V and Sahu P K 2001 Topical cyclosporin A in the management of vernal keratoconjunctivitis Eye 15 39-41
18. Kunert K S, Tisdale A S and Gipson I K 2002 Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine Arch. Ophthalmol. 120 330-7
19. Perry H D, Doshi S J, Donnenfeld E D and Bai G S 2002 Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis Cornea 21 161-3
20. Gokce E H, Sandri G, Bonferoni M C, Rossi S, Ferrari F, Güneri T and Caramella C 2008 Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity Int. J. Pharm. 364 76-86
21. Cortesi R, Esposjto E, Luca G and Nastruzzi C 2002 Production of lipospheres as carriers for bioactive compounds Biomaterials 23 2283-94
22. Yuan H, Wang L L, Du Y Z, You J, Hu F Q and Zeng S 2007 Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification Colloids. Surf. B 60 174-9
23. Lin H R and Sung K C 2000 Carbopol/pluronic phase change solutions for ophthalmic drug delivery J. Control. Release 69 379-88
24. Diebold Y, Jarrín M, Sez V, Carvalho E L, Orea M, Calonge M, Seijo B and Alonso M J 2007 Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP) Biomaterials 28 1553-64
25. Enríquez de Salamanca A, Diebold Y, Calonge M, García-Vazquez C, Callejo S, Vila A and Alonso M J 2006 Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance Invest. Ophthalmol. Vis. Sci. 47 1416-25
26. Lin X, Li X, Zheng L, Yu L, Zhang Q and Liu W 2007 Preparation and characterization of monocaprate nanostructured lipid carriers Colloids Surf. A 311 106-11 (Pubitemid 350026290)
27. Westesen K, Siekmann B and Koch M H J 1993 Investigations on the physical state of lipid nanoparticles by synchroton radiation x-ray diffraction Int. J. Pharm. 93 189-99
28. Lechuga-Ballestros D, Abdul-Fattah A, Stevenson C L and Bennett D B 2003 Properties and stability of a liquid crystal form of cyclosporine-the first reported naturally occurring peptide that exists as a thermotropic liquid crystal J. Pharm. Sci. 92 1821-31
29. Müller R H, Runge S A, Ravelli V, Thünemann A F, Mehnert W and Souto E B 2008 Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation Eur. J. Pharm. Biopharm. 68 535-44
30. Souto E B, Wissing S A, Barbosa C M and Müller R H 2004 Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery Int. J. Pharm. 278 71-7
31. Yuan H, Miao J, Du Y Z, You J, Hu F Q and Zeng S 2008 Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells Int. J. Pharm. 348 137-45